112 related articles for article (PubMed ID: 22330940)
1. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis.
Szulc P
Clin Biochem; 2012 Aug; 45(12):907-19. PubMed ID: 22330940
[TBL] [Abstract][Full Text] [Related]
2. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.
Szulc P; Delmas PD
Osteoporos Int; 2008 Dec; 19(12):1683-704. PubMed ID: 18629570
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of bone health and osteoporosis risk.
Eastell R; Hannon RA
Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
[TBL] [Abstract][Full Text] [Related]
6. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
Boonen S; Ferrari S; Miller PD; Eriksen EF; Sambrook PN; Compston J; Reid IR; Vanderschueren D; Cosman F
J Bone Miner Res; 2012 May; 27(5):963-74. PubMed ID: 22467094
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.
Bergmann P; Body JJ; Boonen S; Boutsen Y; Devogelaer JP; Goemaere S; Kaufman JM; Reginster JY; Gangji V;
Int J Clin Pract; 2009 Jan; 63(1):19-26. PubMed ID: 19125989
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].
Bahlous A; Kalai E; Hadj Salah M; Bouzid K; Zerelli L
Tunis Med; 2006 Nov; 84(11):751-7. PubMed ID: 17294906
[TBL] [Abstract][Full Text] [Related]
11. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
Delmas PD; Vrijens B; Eastell R; Roux C; Pols HA; Ringe JD; Grauer A; Cahall D; Watts NB;
J Clin Endocrinol Metab; 2007 Apr; 92(4):1296-304. PubMed ID: 17244788
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
13. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
14. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?
Devogelaer JP; Boutsen Y; Gruson D; Manicourt D
Rheum Dis Clin North Am; 2011 Aug; 37(3):365-86, v-vi. PubMed ID: 22023897
[TBL] [Abstract][Full Text] [Related]
15. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
Brufsky AM
Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
[TBL] [Abstract][Full Text] [Related]
17. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
[TBL] [Abstract][Full Text] [Related]
18. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
19. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover: Biology and assessment tools.
Szulc P
Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
